Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…Abstract Number: 1328 • 2012 ACR/ARHP Annual Meeting
The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Background/Purpose: Although data are conflicting with regard to the clinical utility of MTX polyglutamates (PGs) measurements as a predictor of the efficacy or toxicity in…Abstract Number: 1301 • 2012 ACR/ARHP Annual Meeting
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of…Abstract Number: 481 • 2012 ACR/ARHP Annual Meeting
Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients
Background/Purpose: Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA) patients and DAS28 remission criteria are widely used, despite their limitations. The purpose…Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting
Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis
Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…Abstract Number: 2661 • 2012 ACR/ARHP Annual Meeting
Disease Activity Score 28-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable?
Background/Purpose: Frequently DAS28-CRP is utilized instead of DAS28-ESR to assess rheumatoid arthritis (RA) disease activity; however, values for remission and low disease activity (LDA) for…Abstract Number: 392 • 2012 ACR/ARHP Annual Meeting
Analysis of Factors Impact On Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis)
Background/Purpose: Patient global assessment (PtGA) is an element of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). This definition has been reported to better…Abstract Number: 2639 • 2012 ACR/ARHP Annual Meeting
Residual Disease Activity in Patients with Early Rheumatoid Arthritis Who Were Classified As Being in Remission According to 8 Different Descriptions: Post Hoc Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort
Background/Purpose: No single gold standard for remission is available for rheumatoid arthritis (RA). All available descriptions, including 2 proposed by an ACR/EULAR committee, allow residual…Abstract Number: 394 • 2012 ACR/ARHP Annual Meeting
Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis
Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA…Abstract Number: 2606 • 2012 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Early Arthritis Patients
Background/Purpose: To investigate patient reported outcomes (PROs) of functioning and health related quality of life (HRQOL) after 1 year remission (DASAbstract Number: 396 • 2012 ACR/ARHP Annual Meeting
Prevalence, Concordance and Predictors of Early and Sustained Remission Assessed by Various Indices in the French Early Arthritis Espoir Cohort
Background/Purpose: Clinical remission is the best achievable state in patients with rheumatoid arthritis (RA). The definition of remission, however, is still under debate. The aim…Abstract Number: 2608 • 2012 ACR/ARHP Annual Meeting
Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Physical function is one of the major outcomes in RA as it predicts work disability, quality of life, health care resource utilisation and mortality.…Abstract Number: 399 • 2012 ACR/ARHP Annual Meeting
Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)
Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is now the goal of therapy to reduce joint damage and disability, and maintain or improve…Abstract Number: 2610 • 2012 ACR/ARHP Annual Meeting
Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis – Results From the Canadian Early Arthritis Cohort
Background/Purpose: Rapid time-to-remission has been associated with sustained remission in established rheumatoid arthritis (RA)1. However, the prevalence and predictive factors of sustained remission in early…Abstract Number: 400 • 2012 ACR/ARHP Annual Meeting
High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission
Background/Purpose: Patient global assessment (PtGA) is a component of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). It has been reported that >50% of…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »